I explore all this in a feature story published today, which marks the kick off of a new series from The Globe and Mail called Skinny Inc, about the big business of weight-loss drugs: Also published today is a companion piece from my colleague Kelly Grant who digs deeper into the research and patient experience of these drugs: We have more coming in the series over the coming weeks, including stories on influencers, insurance coverage, the effect on the food industry and more
Trying to fill your way out of surgical-level laxity often backfires," he explains
Frequently Asked Questions Is Henry Meds legit
While IGF-1 LR3 offers potential benefits for muscle, metabolism, and even skin health, it also carries significant risks that clinicians must discuss with patients
CAS medication safety bulletin: medication safety bulletin: semaglutide
This timeline varies based on how long you were on treatment, your dose, and individual genetic factors affecting hunger hormone recovery speed